Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  2. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  3. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  4. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  5. Psychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  6. Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland
  7. Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  8. Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  9. Psychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  10. Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  11. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
  12. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland
  13. Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Switzerland
  14. Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Prilly
  15. Corresponding Author: Chin B. Eap, PhD, Hôpital de Cery, 1008 Prilly—Lausanne, Switzerland ([email protected]).
  1. Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand suppl. 2005;111(s426):13–20. PubMed CrossRef
  2. HCI Solutions. September 6, 2023. https://compendium.ch/
  3. Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;(11):CD010224. PubMed CrossRef
  4. Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1–13. PubMed CrossRef
  5. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997;24(3):240–244. PubMed CrossRef
  6. Correll CU, Ng-Mak DS, Stafkey-Mailey D, et al. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry. 2017;16(9):1–8. PubMed CrossRef
  7. Verrotti A, D’Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12(5):e32–e43. PubMed CrossRef
  8. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126. PubMed CrossRef
  9. Grootens KP, Meijer A, Hartong EG, et al. Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder. Eur J Clin Pharmacol. 2018;74(11):1485–1489. PubMed CrossRef
  10. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed). 1981;283(6291):577–581. PubMed CrossRef
  11. Pylvänen V, Pakarinen A, Knip M, et al. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006;8(3):643–648. PubMed CrossRef
  12. Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol. 1999;14(8):490–495. PubMed CrossRef
  13. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology. 1999;53(1):230–232. PubMed CrossRef
  14. Kanemura H, Sano F, Maeda Y, et al. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure. 2012;21(7):496–500. PubMed CrossRef
  15. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70(2):65–69. PubMed CrossRef
  16. Nair SS, Harikrishnan S, Sarma PS, et al. Metabolic syndrome in young adults with epilepsy. Seizure. 2016;37:61–64. PubMed CrossRef
  17. Fang J, Chen S, Tong N, et al. Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate. Seizure. 2012;21(8):578–582. PubMed CrossRef
  18. El-Khatib F, Rauchenzauner M, Lechleitner M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure. 2007;16(3):226–232. PubMed CrossRef
  19. Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur J Paediatr Neurol. 2009;13(3):261–268. PubMed CrossRef
  20. Stephen LJ, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001;42(8):1002–1006. PubMed CrossRef
  21. Bowden CL, Calabrese JR, McElroy SL, et al; Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57(5):481–489. PubMed CrossRef
  22. Zuo S, Fries BE, Szafara K, et al. Valproic acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: fat chance, or slim to none? P&T. 2015;40(2):126–132. PubMed
  23. Chang HH, Yang YK, Gean PW, et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord. 2010;124(3):319–323. PubMed CrossRef
  24. Delacrétaz A, Glatard A, Dubath C, et al. Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. Basic Clin Pharmacol Toxicol. 2021;129(1):26–35. PubMed CrossRef
  25. Pylvänen V, Pakarinen A, Knip M, et al. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia. 2006;47(9):1460–1464. PubMed CrossRef
  26. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol. 2000;22(5):361–364. PubMed CrossRef
  27. Aydin K, Serdaroglu A, Okuyaz C, et al. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J Child Neurol. 2005;20(10):848–851. PubMed CrossRef
  28. Martin CK, Han H, Anton SD, et al. Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. J Psychopharmacol. 2009;23(7):814–825. PubMed CrossRef
  29. Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry. 2015;76(11):e1417–e1423. PubMed CrossRef
  30. Abosi O, Lopes S, Schmitz S, et al. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig. 2018;36(1):/j/hmbci.2018.36.issue-1/hmbci-2017-0065/hmbci-2017-0065.xml. PubMed
  31. de Jong M, Belleflamme J, Dale C, et al. Metabolic syndrome in Dutch patients with bipolar disorder: a cross-sectional study. Prim Care Companion CNS Disord. 2018;20(6):27482. PubMed CrossRef
  32. Dubath C, Delacrétaz A, Glatard A, et al. Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. J Clin Psychiatry. 2020;81(3):19m12796. PubMed CrossRef
  33. Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73–96. PubMed CrossRef
  34. Shin JK, Barron CT, Chiu Y-L, et al. Weight changes and characteristics of patients associated with weight gain during inpatient psychiatric treatment. Issues Ment Health Nurs. 2012;33(8):505–512. PubMed CrossRef
  35. Abaseynejad F, Akrami R, Mohebbati R, et al. The effect of sodium valproate on cardiovascular responses in pentylenetetrazol kindling model of epilepsy. Biomed J Sci Tech Res. 2022;42(3):33592–33596.
  36. Zeise ML, Kasparow S, Zieglgänsberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 1991;544(2):345–348. PubMed CrossRef
  37. Kawakami K, Yamada K, Yamada T, et al. Antihypertensive effect of γ-aminobutyric acid-enriched brown rice on spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo). 2018;64(1):56–62. PubMed CrossRef
  38. Shi Z, Yuan B, Taylor AW, et al. Monosodium glutamate is related to a higher increase in blood pressure over 5 years: findings from the Jiangsu Nutrition Study of Chinese adults. J Hypertens. 2011;29(5):846–853. PubMed CrossRef
  39. Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51(2):268–273. PubMed CrossRef
  40. Lee S-Y, Chen S-L, Chang Y-H, et al. Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. J Psychiatr Res. 2013;47(10):1343–1348. PubMed CrossRef
  41. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. PubMed CrossRef
  42. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1-3):103–110. PubMed CrossRef
  43. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders, II: barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138–151. PubMed CrossRef
  44. Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112. PubMed CrossRef
  45. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Focus Am Psychiatr Publ. 2014;12(2):192–204. CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now